drugset / Trial / NCT01887340

Therapeutic Strategy Guided by PET-TDM for Patients With Seminoma

NCT01887340 ↗

Phase 2 Unknown 271 enrolled Gustave Roussy, Cancer Campus, Grand Paris
Non-randomizedParallel-groupOpen-label

Summary

The purpose of the study is to evaluate the ration of patients getting an lighten therapeutic strategy after 18F-fluoro-désoxyglucose positron emission tomography (PET-TDM) in grade I (cohort 1) or metastatic (cohort 2) seminoma

Timeline

Start
2013-06
Primary completion
2016-06
Completion
2026-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule — —
Subject Cisplatin Other / unclassified 20 mg/m2 —
Subject Etoposide Small molecule 100 mg/m2 —

Indications